Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $58.10, moving -0.5% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.16%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, lost 0.3%. Coming into today, shares of the company had gained 9.49% in the past month. In that same time, the Medical sector gained 4.7%, while the S&P 500 gained 3.64%. The investment community will be paying close attention to the earnings pe ...

Shares of Viking Therapeutics (VKTX) have more than tripled in market value in the past year. The upside was triggered by positive updates on its pipeline programs for obesity and non-alcoholic steatohepatitis (NASH) indications. Based on the encouraging results, management intends to meet with the FDA to discuss the late-stage study design and timings for both programs. In the past year, the stock has significantly outperformed the industry's 2.5% decline. The stock has outperformed the sector and the S&P ...

This business has solid results in hand, lots of cash, and more catalysts coming. In biotech, sometimes it's the companies that aren't making a single dime that end up being the very best investments after a short time. For instance, Viking Therapeutics (VKTX -1.54%) doesn't yet have any revenue. But thanks to its ongoing clinical investigations and the high-quality data they're yielding, Viking shares have vaulted 347% in the last 12 months alone. And that might just be the start. So if you're looking to m ...

Shares of Viking Therapeutics (VKTX) fell 6% on Tuesday after pharma giant Eli Lilly (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide). These new vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is available in a single-dose pen (autoinjector), which is priced at about $1,000 for a month's s ...

A monster rival is making aggressive moves in one particular segment. News from a deep-pocketed rival put the hurt on biotech Viking Therapeutics's (VKTX -6.27%) stock on Tuesday. Said rival seems determined to dominate a very hot therapeutic area these days, and it might be tough for a relatively small fry like Viking to compete. On the back of such worries, investors sold out of the biotech, sending its share price down by more than 6% across the trading session. That was on a good day for stocks, general ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...

Shares of Viking Therapeutics (VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, which management plans to advance to late-stage development by early 2025. Last month, alongside its second-quarter earnings results, VKTX reported that it had received feedback from the FDA regarding the next steps in the developmental pathway for the obesity drug VK2735. Based on such feedback, the company is gearing up ...

What Does Viking Therapeutics Do? Viking Therapeutics (VKTX) is a company that develops treatments for metabolic and endocrine disorders. VKTX's focus is on creating medication to address conditions such as steatohepatitis (NASH), a liver disease, as well as obesity and diabetes. Through its expertise in receptor signaling pathways, Viking Therapeutics strives to create therapies that cater to the needs of individuals facing these health challenges, ultimately aiming to improve outcomes over time. America h ...

Given this biotech's ascent, its odds of becoming a giant are better than most. The much-feted biotech Viking Therapeutics (VKTX -0.51%) is aiming for Novo Nordisk's (NVO -1.58%) cash cow, the market for weight loss drugs. If its ambitions are fulfilled, it has a shot at becoming as large as its big pharma rival. To see why this possibility is more than a pipe dream, let's start by making some quick calculations. That will help us to understand Viking's chances of becoming the next Novo Nordisk, based on ho ...